AU2013240842B2 - Process of preparing solifenacin or salt thereof, and novel intermediate used in the process - Google Patents

Process of preparing solifenacin or salt thereof, and novel intermediate used in the process Download PDF

Info

Publication number
AU2013240842B2
AU2013240842B2 AU2013240842A AU2013240842A AU2013240842B2 AU 2013240842 B2 AU2013240842 B2 AU 2013240842B2 AU 2013240842 A AU2013240842 A AU 2013240842A AU 2013240842 A AU2013240842 A AU 2013240842A AU 2013240842 B2 AU2013240842 B2 AU 2013240842B2
Authority
AU
Australia
Prior art keywords
formula
reaction solution
reaction
solifenacin
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013240842A
Other languages
English (en)
Other versions
AU2013240842A1 (en
Inventor
Byoung Suk Lee
Ki Young Lee
Sang Hoon Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyung Dong Pharmaceutical Co Ltd
Original Assignee
Kyung Dong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyung Dong Pharmaceutical Co Ltd filed Critical Kyung Dong Pharmaceutical Co Ltd
Publication of AU2013240842A1 publication Critical patent/AU2013240842A1/en
Application granted granted Critical
Publication of AU2013240842B2 publication Critical patent/AU2013240842B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2013240842A 2012-03-28 2013-03-21 Process of preparing solifenacin or salt thereof, and novel intermediate used in the process Ceased AU2013240842B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120031492A KR101365849B1 (ko) 2012-03-28 2012-03-28 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
KR10-2012-0031492 2012-03-28
PCT/KR2013/002358 WO2013147458A1 (en) 2012-03-28 2013-03-21 Process of preparing solifenacin or salt thereof, and novel intermediate used in the process

Publications (2)

Publication Number Publication Date
AU2013240842A1 AU2013240842A1 (en) 2014-08-28
AU2013240842B2 true AU2013240842B2 (en) 2015-09-03

Family

ID=49260649

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013240842A Ceased AU2013240842B2 (en) 2012-03-28 2013-03-21 Process of preparing solifenacin or salt thereof, and novel intermediate used in the process

Country Status (9)

Country Link
US (1) US9018379B1 (OSRAM)
EP (1) EP2831070A4 (OSRAM)
JP (1) JP5891334B2 (OSRAM)
KR (1) KR101365849B1 (OSRAM)
CN (1) CN104169280A (OSRAM)
AU (1) AU2013240842B2 (OSRAM)
BR (1) BR112014021223A2 (OSRAM)
IN (1) IN2014DN07762A (OSRAM)
WO (1) WO2013147458A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116986986A (zh) * 2023-07-19 2023-11-03 杭州国瑞生物科技有限公司 一种3-氧代-1-环丁烷羧酸中间体的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010103529A1 (en) * 2009-03-09 2010-09-16 Megafine Pharma(P) Ltd. A new method for the preparation of solifenacin and new intermediate thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
AU731387B2 (en) * 1996-03-20 2001-03-29 Scripps Research Institute, The Azatide peptidomimetics
KR100669823B1 (ko) 2001-02-20 2007-01-17 경동제약 주식회사 2-(4-클로로벤조일아미노)-3-[2(1ｈ)-퀴놀리논-4-일]프로피온산의 제조방법 및 그 중간체
WO2004035577A2 (en) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
GB0312426D0 (en) * 2003-05-30 2003-07-09 Albachem Ltd Purification means
EP1714965A4 (en) 2004-02-09 2007-12-19 Astellas Pharma Inc COMPOSITION CONTAINING SOLIFENACINE SUCCINATE
JPWO2005087231A1 (ja) 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
ATE411030T1 (de) * 2004-04-14 2008-10-15 Gilead Sciences Inc Phosphonatanaloga von hiv- integrasehemmerverbindungen
JP4803352B2 (ja) * 2005-07-13 2011-10-26 Ｊｓｒ株式会社 アミノ酸−ｎ−カルボキシ無水物の製造方法
EP1879867A2 (en) * 2005-12-21 2008-01-23 Teva Pharmaceutical Industries Ltd Intermediates for preparing solifenacin
EP2102200A2 (en) 2006-11-22 2009-09-23 Medichem, S.A. An improved process for the synthesis of solifenacin
CN101711248A (zh) * 2007-03-30 2010-05-19 医药化学公司 一种改进的素非那新合成工艺
WO2009011844A1 (en) * 2007-07-13 2009-01-22 Teva Pharmaceutical Industries Ltd. Processes for solifenacin preparation
HUE054585T2 (hu) * 2008-04-29 2021-09-28 Ascendis Pharma Endocrinology Div A/S Pegilezett rekombináns humán növekedési hormon vegyületek
US8178700B2 (en) * 2009-05-04 2012-05-15 International Business Machines Corporation Method of preparing cyclic carbonates, cyclic carbamates, cyclic ureas, cyclic thiocarbonates, cyclic thiocarbamates, and cyclic dithiocarbonates
WO2011030139A1 (en) * 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010103529A1 (en) * 2009-03-09 2010-09-16 Megafine Pharma(P) Ltd. A new method for the preparation of solifenacin and new intermediate thereof

Also Published As

Publication number Publication date
EP2831070A4 (en) 2015-08-19
JP5891334B2 (ja) 2016-03-22
IN2014DN07762A (OSRAM) 2015-05-15
KR101365849B1 (ko) 2014-02-24
EP2831070A1 (en) 2015-02-04
WO2013147458A1 (en) 2013-10-03
JP2015510927A (ja) 2015-04-13
CN104169280A (zh) 2014-11-26
US9018379B1 (en) 2015-04-28
AU2013240842A1 (en) 2014-08-28
BR112014021223A2 (pt) 2020-10-27
KR20130109609A (ko) 2013-10-08
US20150112072A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
JP2021522236A (ja) ジアステレオマー酒石酸エステルによるラセミ体分割による（４ｓ）−４−（４−シアノ−２−メトキシフェニル）−５−エトキシ−２，８−ジメチル−１，４−ジヒドロ−１，６−ナフチリジン−３−カルボキサミドを調製する方法
CA2914381A1 (en) An efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl] methoxy]propyl]adenine
CN114014787B (zh) 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法
HRP20040606A2 (en) A process for producing phenserine and its analog
EP2029587A2 (en) Process for the preparation of solifenacin
WO2009010987A1 (en) An improved process for the preparation of pure palonosetron hydrochloride
CN111072633A (zh) 一种埃索美拉唑镁三水合物的制备方法
JP7837559B2 (ja) （ｒ）－４－（１－（６－（４－（トリフルオロメチル）ベンジル）－６－アザスピロ［２．５］オクタン－５－カルボキサミド）－シクロプロピル）安息香酸又はその塩の調製方法
AU2013240842A1 (en) Process of preparing solifenacin or salt thereof, and novel intermediate used in the process
CN116496214B (zh) 一种手性3-(n-甲基-1,2,3,4-四氢异喹啉)丙酸酯苯磺酸盐的制备方法
EP1698615B1 (en) Method of obtaining tolterodine
KR100990046B1 (ko) 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
EP2345655A1 (en) A process for racemisation of 6-(5-chloropyridin-2-yl)-7-(4-methyl-1-piperazinyl)carbonyloxy-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CN107216332B (zh) 叔丁基-7-羟甲基-7,8-二氢4h吡唑并二氮杂卓5(6h)甲酸基酯的合成方法
KR20120022421A (ko) 신규의 로수바스타틴 엔-메틸벤질아민 염 및 그의 제조방법
WO2001025236A2 (en) A stereoselective process for the preparation of endo-3-aminoazabicycloalkanes
US10207986B2 (en) Method for preparing D-arginine
US8242276B2 (en) Methods for the preparation of N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt
JP6038800B2 (ja) 光学活性アルコールの製造方法
KR100929414B1 (ko) 트로스피움 클로라이드의 제조방법
EP4438598A1 (en) Method for preparing arylethene compound
CN117586177A (zh) 一种阿维巴坦中间体的制备方法
KR101298046B1 (ko) 솔리페나신과 이의 염의 효율적 제조방법
EP2855421B1 (en) Process for the preparation of optically active 3,3-diphenylpropylamines
CA2660348A1 (en) A novel process for preparing 3-amino-5-fluoro-4-dialkoxypentanoic acid ester

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired